Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
Part of paid clinical trials in Baltimore, Maryland.
- Sponsor
- Johns Hopkins University
- Study ID
- NCT07521930
- Status
- Recruiting
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Brain Stem Stroke
- Muscular Atrophy, Progressive
- Muscular Disorders, Atrophic
- Muscular Dystrophies
- Pontine Hemorrhage
- Pontine Infarction
- Spinal Cord Injuries (SCI)
- Tetraplegia/Tetraparesis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- INTENT Neural Interface System — DEVICEUp to eight microelectrode arrays will be implanted on motor, sensory, and integrative cortex, connected to up to three percutaneous pedestals. Neural recording and stimulation will occur during study visits that will occur at least weekly and up to five days per week throughout the study.
Study Details
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different areas of the brain to allow adults affected by disabling paralysis (see Eligibility for more details) to control and receive feedback from assistive devices.
Key Dates
- Start date
- Jun 30, 2026
- Status verified
- Apr 2026
- Primary completion
- Jun 30, 2028
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 5 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DEVICE_FEASIBILITY
Arms
- Experimental: INTENT Neural Interface SystemINTENT Neural Interface System
Primary Outcome Measure
Incidence of Device-Related Adverse Events [Safety and Tolerability] [ Time Frame: 54 weeks ]
Central Contacts
- Nathan E Crone, MD4109559441
- Francesco Tenore, PhD4437789774
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Johns Hopkins Medicine | Baltimore | Maryland | 21205 |
Find similar trials in Baltimore, MD
By research site
Related Studies
- Safety Study of XT-150 in Participants With ALSPHASE1 · Not Yet Recruiting · Xalud Therapeutics, Inc. · Phoenix, Arizona
- Study of COYA 302 for the Treatment of ALSPHASE2 · Recruiting · Coya Therapeutics · Phoenix, Arizona
- Retinal Imaging in Neurodegenerative DiseaseRecruiting · Duke University · Durham, North Carolina
- ECoG BMI for Motor and Speech ControlRecruiting · Karunesh Ganguly · San Francisco, California